Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristi Tesarz

Physician Assistant Southfield, MI Physician Assistant

NPI 1740367036 CMS profile 11211238

26206 W 12 Mile Rd Ste 202, Southfield, MI 48034

Open in the dashboard

General payments

$11,863

581 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristi Tesarz of Southfield, MI is reported in the CMS Open Payments database as having received $11,863 across 581 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,799 71
2024 General $1,866 102
2023 General $2,094 110
2022 General $3,351 149
2021 General $2,753 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristi Tesarz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kristi Tesarz were reported at $1,799. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kristi Tesarz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,753 $132 $37–$438 $132
2022 $3,351 $155 $48–$522 $149
2023 $2,094 $167 $52–$557 $160
2024 $1,866 $178 $55–$600 $164
2025 $1,799 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,964 111 payments
  2. AbbVie, Inc. $1,646 86 payments
  3. Lilly USA, LLC $920 68 payments
  4. Amgen Inc. $842 28 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $734 35 payments
  6. Astellas Pharma US Inc $703 28 payments
  7. Janssen Pharmaceuticals, Inc $685 18 payments
  8. AstraZeneca Pharmaceuticals LP $625 32 payments
  9. GlaxoSmithKline, LLC. $509 26 payments
  10. Pfizer Inc. $449 21 payments
  11. Other $2,786 128 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,774 580 payments
  2. Education $89 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,125 70 payments
  2. Ozempic $841 65 payments
  3. XARELTO $685 18 payments
  4. VRAYLAR $658 31 payments
  5. UBRELVY $501 29 payments
  6. Wegovy $483 23 payments
  7. MOUNJARO $467 38 payments
  8. TRELEGY ELLIPTA $460 22 payments
  9. Repatha $390 11 payments
  10. JARDIANCE $380 25 payments
  11. Other $7,998 414 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

9,003

Median for Physician Assistant: 241

Drug cost

$901,407

Median for Physician Assistant: $4,110

Branded share of claims

19.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 125 $189,071
Jardiance Empagliflozin Brand 111 $144,564
Eliquis Apixaban Brand 91 $118,450
Mounjaro Tirzepatide Brand 43 $55,059
Trulicity Dulaglutide Brand 25 $51,764
Januvia Sitagliptin Phosphate Brand 29 $42,344
Xarelto Rivaroxaban Brand 26 $33,366
Rybelsus Semaglutide Brand 11 $29,241
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $26,293
Myrbetriq Mirabegron Brand 28 $24,411

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $255
$255 26 —
Wegovy
  • Novo Nordisk Inc $151
$151 — —
JARDIANCE
  • Lilly USA, LLC $75
  • Boehringer Ingelheim Pharmaceuticals, Inc. $73
$147 111 —
MOUNJARO
  • Lilly USA, LLC $137
$137 43 —
VRAYLAR
  • AbbVie, Inc. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

581 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record